These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31790636)

  • 41. The emerging roles of DOT1L in leukemia and normal development.
    McLean CM; Karemaker ID; van Leeuwen F
    Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL.
    Yang W; Tran P; Khan Z; Rezk S; O'Brien S
    Leuk Lymphoma; 2017 Jun; 58(6):1498-1501. PubMed ID: 27774846
    [No Abstract]   [Full Text] [Related]  

  • 43. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
    Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
    Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
    Gibbons GS; Chakraborty A; Grigsby SM; Umeano AC; Liao C; Moukha-Chafiq O; Pathak V; Mathew B; Lee YT; Dou Y; Schürer SC; Reynolds RC; Snowden TS; Nikolovska-Coleska Z
    Eur J Med Chem; 2020 Mar; 189():112023. PubMed ID: 31978781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional interdependence of BRD4 and DOT1L in MLL leukemia.
    Gilan O; Lam EY; Becher I; Lugo D; Cannizzaro E; Joberty G; Ward A; Wiese M; Fong CY; Ftouni S; Tyler D; Stanley K; MacPherson L; Weng CF; Chan YC; Ghisi M; Smil D; Carpenter C; Brown P; Garton N; Blewitt ME; Bannister AJ; Kouzarides T; Huntly BJ; Johnstone RW; Drewes G; Dawson SJ; Arrowsmith CH; Grandi P; Prinjha RK; Dawson MA
    Nat Struct Mol Biol; 2016 Jul; 23(7):673-81. PubMed ID: 27294782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
    Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
    Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
    Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
    ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
    Steinhilber D; Marschalek R
    Biochem Pharmacol; 2018 Jan; 147():183-190. PubMed ID: 28943239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
    Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
    Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MLL translocations, histone modifications and leukaemia stem-cell development.
    Krivtsov AV; Armstrong SA
    Nat Rev Cancer; 2007 Nov; 7(11):823-33. PubMed ID: 17957188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
    Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
    Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation.
    Cao K; Ugarenko M; Ozark PA; Wang J; Marshall SA; Rendleman EJ; Liang K; Wang L; Zou L; Smith ER; Yue F; Shilatifard A
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27365-27373. PubMed ID: 33077595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
    Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
    J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
    Barry ER; Corry GN; Rasmussen TP
    Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
    Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
    J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
    Zhang L; Chen Y; Liu N; Li L; Xiao S; Li X; Chen K; Luo C; Chen S; Chen H
    Bioorg Chem; 2018 Oct; 80():649-654. PubMed ID: 30059890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
    Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
    Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
    Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA
    Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.